Latigo Biotherapeutics, Inc. (LTGO)

Latigo Biotherapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Income Operating Income Growth	-112.38	-110.39	-63.45
Net Income Net Income Growth	-111.14	-109.17	-61.18
Earnings Per Share EPS Growth	-116.74	-129.23	-90.10
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	55	69.44	17.92
Total Debt Total Debt Growth	31.25	0.69	0.85
Net Cash (Debt) Net Cash Growth	23.75	68.75	17.07
Net Cash Growth	-	302.81%	-
Net Cash Per Share Net Cash Per Share Growth	24.95	81.38	25.13

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	-103.19	-97.56	-50.96
Capital Expenditures CapEx Growth	-0.11	-0.14	-0.07
Free Cash Flow Free Cash Flow Growth	-103.3	-97.69	-51.03
Free Cash Flow Growth	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Sep 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 23, 2026

Data Sources Report a data error